Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - Results from a nationwide cohort in Germany (GRAID)

Lupus

Volumn 22, Issue 11, 2013, Pages 1142-1149

  Witt, M ^a   Grunke, M ^a   Proft, F ^a   Baeuerle, M ^b   Aringer, M ^c   Burmester, G ^d   Chehab, G ^e   Fiehn, C ^f   Fischer Betz, R ^e   Fleck, M ^g   Freivogel, K ^h   Haubitz, M ⁱ   Kotter I ^j   Lovric, S ^k   Metzler, C ^l   Rubberth Roth, A ^m   Schwarting, A ⁿ   Specker, C ^o   Tony, H P ^p   Unger, L ^q   Wassenberg, S ^r   Dorner T ^d   Schulze Koops, H ^a   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f Center for Rheumatic Diseases   (Germany)

^g UNIVERSITY OF REGENSBURG   (Germany)

^h Analytica International GmbH   (Germany)

ⁱ KLINIKUM FULDA   (Germany)

^j Rheumatology Outpatient Clinic   (Germany)

^k HANNOVER MEDICAL SCHOOL   (Germany)

^l Barmherzige Brueder Hospital   (Germany)

^m UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁿ JOHANNES GUTENBERG UNIVERSITY   (Germany)

^o Kliniken Essen Sued   (Germany)

^p UNIVERSITY OF WÜRZBURG   (Germany)

^q ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

^r Evangelisches Fachkrankenhaus Ratingen ^*  (Germany)

more..

Author keywords

B lymphocytes; cohort studies; efficacy; rituximab; safety; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; ASCITES; BACTERIAL INFECTION; BACTERIAL MENINGITIS; BONE MARROW TOXICITY; CELLULITIS; DISEASE DURATION; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG SAFETY; ERYTHEMA; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; GERMANY; HERPES LABIALIS; HUMAN; INFECTION; INFLAMMATION; INFORMATION PROCESSING; JOINT SWELLING; KIDNEY FAILURE; LABORATORY TEST; LEUKOPENIA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYALGIA; NAUSEA; NEPHRITIS; OUTCOME ASSESSMENT; PLEURISY; PRIORITY JOURNAL; PROTEINURIA; PSEUDOMEMBRANOUS COLITIS; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TRACHEOBRONCHITIS; TREATMENT FAILURE; URINARY TRACT INFECTION; VIRUS INFECTION; WEIGHT REDUCTION; WELLBEING;

B LYMPHOCYTES; COHORT STUDIES; EFFICACY; RITUXIMAB; SAFETY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; COHORT STUDIES; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; OFF-LABEL USE; RETROSPECTIVE STUDIES;

EID: 84884540521     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313503912     Document Type: Article

References (35)

1. Edwards JC, Cambridge G. B-cell targeting in rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol. 2006 ; 6: 394-403
2. Dörner T, Radbruch A, Burmester GR. B-cell-directed therapies for autoimmune disease. Nat Rev Rheumatol. 2009 ; 5: 433-441
3. Zandman-Goddard G, Orbach H, Shoenfeld Y. Novel approaches to therapy for systemic lupus erythematosus: Update 2005. Expert Rev Clin Immunol. 2005 ; 1: 223-238
4. Dörner T, Isenberg D, Jayne D, Wiendl H, Zillikens D, Burmester G. Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. Autoimmun Rev. 2009 ; 9: 82-89
5. Stone JH, Merkel PA, Spiera R, et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med. 2010 ; 363: 221-232
6. Jones RB, Tervaert JW, Hauser T, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010 ; 363: 211-220
7. Leandro MJ, Edwards JC, Cambridge G, Ehrenstein MR, Isenberg DA. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum. 2002 ; 46: 2673-2677
8. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: The first fifty patients. Arthritis Rheum. 2009 ; 61: 482-487
9. Isenberg DA. Rituximab - it was the best of times, it was the worst of times. Autoimmun Rev. 2012 ; 11: 790-791
10. Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011 ; 20: 709-716
11. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012 ; 64: 1215-1226
12. Fernández-Nebro A, de la Fuente JM, Carreño L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study. Lupus. 2012 ; 21: 1063-1076
13. Weidenbusch M, Rommele C, Schrottle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013 ; 28: 106-111
14. Díaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev. 2012 ; 11: 357-364
15. Andrade-Ortega L, Irazoque-Palazuelos F, López-Villanueva R, et al. Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study [in Spanish]. Reumatol Clin. 2010 ; 6: 250-255
16. Turner-Stokes T, Lu TY, Ehrenstein MR, Giles I, Rahman A, Isenberg DA. The efficacy of repeated treatment with B-cell depletion therapy in systemic lupus erythematosus: An evaluation. Rheumatology (Oxford). 2011 ; 50: 1401-1408
17. van Vollenhoven RF. Rituximab - shadow, illusion or light?. Autoimmun Rev. 2012 ; 11: 563-567
18. Tony HP, Burmester G, Schulze-Koops H, et al. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: Experience from a national registry (GRAID). Arthritis Res Ther. 2011 ; 13: R75 - R75
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
20. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
21. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003 ; 13: 176-181
22. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet. 2011 ; 377: 721-731
23. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 ; 63: 3918-3930
24. Manzi S, Sánchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: Combined results from two phase III trials. Ann Rheum Dis. 2012 ; 71: 1833-1838
25. Hay EM, Bacon PA, Gordon C, et al. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993 ; 86: 447-458
26. Bang SY, Lee CK, Kang YM, et al. Multicenter retrospective analysis of the effectiveness and safety of rituximab in Korean patients with refractory systemic lupus erythematosus. Autoimmune Dis. 2012 ; 2012: 565039-565039
27. Jonsdottir T, Zickert A, Sundelin B, Henriksson EW, van Vollenhoven RF, Gunnarsson I. Long-term follow-up in lupus nephritis patients treated with rituximab - clinical and histopathological response. Rheumatology (Oxford). 2013 ; 52: 847-855
28. Isvy A, Meunier M, Gobeaux-Chenevier C, et al. Safety of rituximab in rheumatoid arthritis: A long-term prospective single-center study of gammaglobulin concentrations and infections. Joint Bone Spine. 2012 ; 79: 365-369
29. Curtis JR, Xie F, Chen L, et al. The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. Ann Rheum Dis. 2011 ; 70: 1401-1406
30. Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011 ; 127: 303-312; quiz 13-14
31. Gough AK, Foo J. Current treatment of rheumatoid arthritis. BMJ. 2011 ; 343: d7050; author reply d2 - d7050; author reply d2
32. van Vollenhoven RF, Emery P, Bingham CO, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010 ; 37: 558-567
33. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010 ; 62: 2625-2632
34. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010 ; 62: 2458-2466
35. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soto MJ. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore). 2008 ; 87: 345-364